An interventional study of Additional margin coagulation in Liver Cancer and Cancer, Treatment-Related, sponsored by Hospital del Mar. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Hospital del Mar · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Liver Neoplasms with a site in Spain — 7 open to participants now, 17 under way, 4 of them phase 3. Liver Neoplasms · Spain.
Among the 48 studies in Liver Neoplasms with a site in Spain, this one is the 5th largest by planned enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2023, is one of 6 with no phase, reaches primary completion later than 14 of the 16 other live ones, and was the 42nd registered.
1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.
Browse Liver Neoplasms studies →7 of the 48 studies in Liver Neoplasms with a site in Spain are open now. Recruiting first, the newest first:
AbbVie · Sites in Spain, United States, China and 4 more countries
Ages 18+
Hospital Universitario La Fe · Sites in Spain
Ages 18–65
Maastricht University Medical Center · Sites in Spain, United States, Australia and 10 more countries
Ages 18+
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) · Sites in Spain
Ages 18+
Prof. Valérie Mc Lin · Sites in Spain, United States, Australia and 13 more countries
Ages 1 days+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 10 · Phase 3 15
First in 1999; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 720 is above the median of 47 across 929 interventional studies indexed under Liver Neoplasms.
Median enrollment 201 across the 39 interventional studies, 500 across the 9 observational. Of the 28 that completed or were terminated, 15 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 48 have an industry lead sponsor. The 10 most frequent:
Hospital del Mar is the lead sponsor of 45 studies on the registry; 17 are open to participants now.
Hospital del Mar has 1 study filed under Liver Neoplasms — fewer than ten, so there is no comparison to draw.
5 of the studies in Liver Neoplasms with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02954094Target PharmaSolutions, Inc.A Longitudinal Observational Study of the Natural History and Management of Patients With HCC | 2027-02 |
| NCT04008797Eisai Inc.A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | 2027-03-31 |
| NCT06923761Grey Wolf TherapeuticsEMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1) | 2027-04-30 |
| NCT05063565Boston Scientific CorporationTheraSphere With Durvalumab and Tremelimumab for HCC | 2027-06 |
| NCT07717437Maastricht University Medical CenterDRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection. | 2027-11-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 48 studies in Liver Neoplasms with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Radiofrequency devices have been increasingly employed in liver surgery in order to achieve proper hemostasis and this use has become more evident with the implementation of minimal invasive surgery. Due to its well-known efficacy for tumor ablation (i.e. hepatocarcinoma) it use has been extended in some cases to ablate the liver surface after resection in questionable resection. Till date, despite the majority of surgeons apply an additional coagulation in doubtful margins, there is not an evidence that this maneuver really decreases the local recurrence or increases the overall survival. On the contrary, some studies have suggested that non-anatomical resections in order to spare liver parenchyma could lead to major zones of liver ischemia in the remnant liver and thus favoring recurrence. However, major liver ischemia (defined as grade 2 o more) is unlikely to be provoked by 1 cm-depth additional coagulation of the margin.
The investigators previously published in a retrospective study the concept of additional margin coagulation within liver resections and narrow margins and demonstrated that the study group had significantly less local recurrence compared to the controls. Therefore, in the present study the aim is to continue this evaluation through a multicenter randomized clinical trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this arm it will be permitted one/several conventional methods according to surgeon preference: * Conventional crusch-clamp or finger fracture technique * Ultrasonic dissector (CUSA, SONOK..) or Ultrasonic mediated devices * Water jet dissector * Argon beam coagulator
In this arm it will be permitted to use the radiofrequency devices which have demonstrated evidence in the literature in terms of reducing local recurrence alone or in combination with any conventional method described previously in Arm. (Coolingbis device by VecMedical as well as Aquamantys (Medtronic) These devices and their operating procedure have been described in detail elsewhere Briefly, it consists of a handheld instrument that might be employed not only for margin coagulation but also as hemostatic instrument. After performing the hepatectomy the bladeless part of the device should be applied onto the surgical margin following the protocol 3-4 s/cm2 of liver transection surface at maximum power output.in order to perform an additional margin coagulation
Procedure: Additional margin coagulation
After performing the hepatectomy the selected device should be applied onto the surgical margin following the protocol 3-4 s/cm2 of liver transection surface at maximum power output in order to perform an additional margin coagulation
Local recurrence
Local recurrence (LR): defined as any growing or enhancing tumour in the margin of hepatic resection specifically reviewed to this aim in a later follow-up imaging
Time frame: 5 years follow-up
overall survival (OS)
defined as time from surgery until death or the end of the study, patients who discontinue from the study without disease will be censored at the time of their last tumour evaluation prior to death or discontinuation.
Time frame: From the surgery to death or lost of follow-up whichever came first, assessed up to 24 months
Disease free survival (DFS)
Disease free survival (DFS), calculated as the time from surgery until disease progression, patients who have not progressed at the time the SVR analysis is performed will be censored at the time of their last tumour evaluation
Time frame: 2 years of follow-up
Cancer specific survival (CSS)
Cancer-specific survival (CSS), measured from the date of surgery to the date of death from colorectal cancer/HCC or last follow-up.
Time frame: From the surgery to recurrence/last follow-up whichever came first, assessed up to 24 months
Postoperative complications
Graded by Clavien-Dindo clasification and CCI
Time frame: 90 days after surgery
Hepatic recurrence
Tumoral recurrence within the liver
Time frame: From the surgery to hepatic recurrence or lost of follow-up whichever came first, assessed up to 24 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Nov 2023 (actual). Primary completion is estimated for May 2028, 54 months after the start.
Of 149 non-industry interventional studies with no phase under Liver Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 73. This study's planned 54 months is above that.
Counting every sponsor, half of 168 studies reached it within 39 months; a quarter within 18 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital del Mar